Dr. Eduard Ayuso is Chief Executive Officer of SIEGFRIED DINAMIQS (Zurich, Switzerland), a CDMO providing a comprehensive range of manufacturing services, process development, quality control and analytics solutions to support and optimize the most promising gene therapy projects. Dr. Ayuso is an expert in the field of gene therapy using viral vector platforms, including adenoviral vectors, helper-dependent adenoviral vectors, and adeno-associated vectors (AAV), as well as their design, manufacture, and purification. With over two decades of academic and industry consulting experience, he has made significant contributions to the field of in vivo gene transfer in small and large animal models of diseases, as well as AAV vector development and analytics. From 2020 to 2023, Dr Ayuso was Chief Technology Officer at DiNAQOR (Zürich, Switzerland), a genetic medicine platform company focused on addressing severe inherited cardiac and kidney diseases. Dr. Ayuso previously served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at University of Nantes. From 2018 to 2022, he has served as vice president of the French Society for Gene and Cell Therapy. He is also chairman of the manufacturing committee of the European Society for Gene and Cell Therapy. Dr. Ayuso earned his Ph.D. in Biochemistry and Molecular Biology and his degree in Veterinary Medicine from Autonomous University of Barcelona.